98%
921
2 minutes
20
Background: Hepatocellular carcinoma (HCC) is a recognized sequalae of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. This study aimed to identify long-term survival and prognostic factors after curative resection for HCC among patients with chronic HCV infection.
Methods: From a Chinese multicenter database, the data of consecutive patients with HCV infection undergoing curative liver resection for initial HCC between 2006 and 2015 were retrospectively reviewed. Postoperative 30-day mortality and morbidity, long-term overall survival (OS) and recurrence-free survival (RFS) were evaluated.
Results: Among 382 HCC patients with HCV infection, 68 (18%) had concurrent HBV infection and 110 (29%) had portal hypertension. Postoperative 30-day morbidity and mortality rates were 45% and 2.9%, respectively. The 5-year OS and RFS rates were 45% and 34%, respectively. Multivariable Cox-regression analyses identified that concurrent HBV infection, presence of portal hypertension, largest tumor size > 5 cm, and macrovascular and microvascular invasion were independently associated with worse OS and RFS, while postoperative regular anti-HCV therapy was independently associated with better OS.
Conclusion: Long-term prognosis after HCC resection among patients with HCV infection was worse in those with concurrent HBV infection and concomitant portal hypertension. Postoperative regular anti-HCV therapy was associated with better OS.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.hpb.2020.04.006 | DOI Listing |
Pediatr Transplant
November 2025
Department of Medicine, Division of Nephrology, Columbia University Vagelos College of Physicians & Surgeons, New York, New York, USA.
Background: Changes to the calculation of the Kidney Donor Profile Index (KDPI) have lowered the KDPI of hepatitis C (HCV+) donor kidneys; therefore, increasing the proportion of pediatric-prioritized kidneys that are HCV+. We aimed to study consent rates for HCV+ kidneys among pediatric kidney transplant candidates.
Methods: We identified pediatric candidates waitlisted from 2019 to 2024 and excluded those who received a living donor transplant.
Med J Aust
September 2025
QIMR Berghofer, Brisbane, QLD.
Objective: To determine the cumulative incidence of overall and cause-specific mortality among Queensland residents admitted to hospital with cirrhosis during 2007-22, by cirrhosis aetiology.
Study Design: Retrospective cohort study; analysis of linked Queensland Hospital Admitted Patient Data Collection and Queensland Registry of Births, Deaths and Marriages data.
Setting, Participants: Adult Queensland residents (18 years or older) admitted to Queensland hospitals with cirrhosis during 1 July 2007 - 31 December 2022.
J Formos Med Assoc
September 2025
Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Center of Hepatitis Research, College of Medicine and Center of Metabolic Disorders and Obesity, Kaohsiung Medical University, Kaohsiung, Taiwan. Electroni
Hepatol Res
September 2025
Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Izunokuni, Shizuoka, Japan.
Aim: Hepatitis C virus (HCV) infection remains a global health concern. Although the World Health Organization (WHO) proposed a strategy to eliminate HCV by 2030, Japan faces challenges owing to limited access and insufficient support for high-risk populations. Previously, HCV diagnoses required a two-step process, delaying results and increasing costs.
View Article and Find Full Text PDFJHEP Rep
October 2025
HEOR-Global Value and Access, Gilead Sciences, Inc., Foster City, CA, USA.
Background & Aims: HDV leads to the most severe form of viral hepatitis. It has been estimated to affect 5-13% of people who have chronic HBV worldwide. Evidence of HDV incidence, prevalence, and disease burden in Spain is limited.
View Article and Find Full Text PDF